Search - tctmd.com

Displaying 61 - 80 of 376

Sort: Relevancy | Date

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

News Conference News AHA 2024

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

Yael L. Maxwell

November 20, 2024

Nasal Bumetanide Safe, Effective in Healthy Adults

News Conference News AHA 2024

Nasal Bumetanide Safe, Effective in Healthy Adults

Yael L. Maxwell

November 18, 2024

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

News Conference News AHA 2024

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

November 17, 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

News Conference News AHA 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

Michael O'Riordan

November 16, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

News Features

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

November 13, 2024

October 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

October 2024 Dispatch for the CV Team

October 25, 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

News Conference News HFSA 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

October 04, 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

News Conference News HFSA 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

Michael O'Riordan

October 03, 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

News Conference News HFSA 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

October 02, 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

HFSA Stats 2024 a ‘Call to Action’ Against Rising Tide of HF

News Daily News

HFSA Stats 2024 a ‘Call to Action’ Against Rising Tide of HF

October 01, 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

October 01, 2024

HFSA Cancels Annual Meeting Due to Looming Hurricane

News Daily News

HFSA Cancels Annual Meeting Due to Looming Hurricane

September 26, 2024

Yes, Clinical Inertia IS the Leading Cause of GDMT Underuse in HFrEF

News Daily News

Yes, Clinical Inertia IS the Leading Cause of GDMT Underuse in HFrEF

September 20, 2024

Subcutaneous Furosemide Enables HF Patients to Address Congestion at Home

News Daily News

Subcutaneous Furosemide Enables HF Patients to Address Congestion at Home

September 16, 2024

TCTMD’s Top 10 Most Popular Stories for August 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2024

September 03, 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

September 01, 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

News Conference News ESC 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

August 31, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.